HRMY — Harmony Biosciences Holdings, Inc.

Harmony Biosciences (HRMY) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Product Revenue: $243.8 million, a 21% increase from $201.3 million in Q4 2024.
• Full Year 2025 Net Product Revenue: $868.5 million, marking six consecutive years of revenue growth and profitability.
• Non-GAAP Adjusted Net Income: $33.4 million ($0.57 per diluted share), down from $64.2 million ($1.10 per diluted share) in the prior year.
• Operating Expenses: Increased to $136.7 million from $91.1 million, driven by R&D investments, commercialization efforts, and litigation expenses.
• Cash Position: $882.5 million in cash and investments, with $348.2 million generated from operations in 2025.

2. Strategic Updates and Business Highlights

• WAKIX Performance: Achieved approximately 400 average patient additions for three consecutive quarters, totaling around 8,500 patients. The company aims for WAKIX to reach blockbuster status in 2026 with projected revenues of $1 billion to $1.04 billion.
• Intellectual Property (IP) Developments: Settled with 6 of 7 generic filers, delaying potential generic entry until March 2030 if pediatric exclusivity is granted.
• Pipeline Advancements: Five ongoing Phase III trials across distinct CNS indications, including new formulations of pitolisant (pitolisant GR and HD) targeting narcolepsy and orphan diseases.
• FDA Approval: WAKIX approved for treating cataplexy in pediatric patients aged 6 and older, enhancing its market potential.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated guidance for WAKIX net revenue of $1 billion to $1.04 billion.
• PDUFA Dates: Anticipated NDA submission for pitolisant GR in Q2 2026, with a target PDUFA date in Q1 2027. Pitolisant HD expected to have top-line data in 2027 and PDUFA in 2028.
• Sales Force Expansion: Plans to increase field-based teams by approximately 20% to enhance market presence and support growth.

4. Bad News, Challenges, or Points of Concern

• Decline in Non-GAAP Income: Notable decrease in adjusted net income compared to the previous year, raising concerns about profitability sustainability amidst rising expenses.
• Litigation Risks: Ongoing ANDA litigation could pose risks, especially if outcomes are unfavorable. The company remains confident but acknowledges the uncertainty of legal processes.
• Competitive Pressures: The presence of competitors in the CNS space, particularly in narcolepsy and idiopathic hypersomnia, could impact enrollment and market share.

5. Notable Q&A Insights

• EPX-100 for Dravet Syndrome: Discussion on baseline seizure rates and the competitive landscape highlighted the drug's potential efficacy and safety profile compared to existing treatments.
• Orexin-2 Receptor Agonist: Plans for mid-2026 data release and exploration of broader indications beyond narcolepsy were discussed, indicating a strategic focus on expanding therapeutic applications.
• Pediatric Cataplexy Indication: The approval is expected to enhance WAKIX's market position, with the pediatric population representing about 5% of the total narcolepsy market.
• Sales Force Impact: The expansion is aimed at improving market share and is expected to yield results following the onboarding of new personnel by the end of Q1 2026.

Overall, Harmony Biosciences demonstrated strong financial performance in 2025, with significant growth in WAKIX revenue and a robust pipeline. However, challenges related to litigation and competitive pressures remain critical points of focus as the company moves into 2026.